Is this man the "Edward Snowden" of Obamacare?

Controversial manuscript holds medical treatments to be banned…       April 30, 2014           Is this man the "Edward Snowden" of Obamacare? Dear Rude Awakening Reader, A patriotic whistleblower has released a shocking video that has gone viral… In it he reveals a controversial manuscript that may hold the cures and treatments to cancer, diabetes, Alzheimer's, arthritis, heart disease, and more. But that's not the shocking part. The shocking part is this whistle blower reveals some little-known provisions in Obamacare that could make them all illegal! ==> Is this man the "Edward Snowden" of Obamacare? Sincerely, Greg Guenthner Managing Editor, Rude Awakening                     The Rude Awakening is committed to protecting and respecting your privacy. We do not rent or share your email address. By submitting your email address, you consent to Agora Financial delivering daily email issues and advertisements. To end your Rude Awakening e-mail subscription and associated external offers sent from The Rude Awakening, click here. Please read our Privacy Statement. For any further comments or concerns please email us at rude@agorafinancial.com. If you are you having trouble receiving your Rude Awakening subscription, you can ensure its arrival in your mailbox by whitelisting the Rude Awakening. © 2014 Agora Financial, LLC. 808 Saint Paul Street, Baltimore MD 21202. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in any security they personally recommend to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Caleb